ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2017
Tumor-induced osteomalacia: experience from a South American academic center.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Persistence and recurrence in tumor-induced osteomalacia: A systematic review of the literature and results from a national survey/case series.Endocrine · 2022Pooled it
- Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2021Trial
- Tumor-Induced Osteomalacia: A Case Report of Rare Disease and Literature review.South Asian journal of cancer · 2025Article
- Factors associated with impaired physical functionality in X-linked hypophosphatemia.JBMR plus · 2025Article
- Latent phosphaturic mesenchymal tumor in left planta detected by [European journal of nuclear medicine and molecular imaging · 2024Article
- Oncogenic Osteomalacia: Challenges in Diagnosis.Indian journal of surgical oncology · 2023Article
- A diagnostic challenge of mysterious bone pain caused by tumor-induced osteomalacia with multiple tumors: a case report.Translational cancer research · 2023Article
- Article
- Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors.Diagnostics (Basel, Switzerland) · 2022Review
- Ameloblastic Fibroodontoma of Mandible Causing Tumor Induced Osteomalacia: A Case Report with Review of 88 Phosphaturic Oral Neoplasms.Head and neck pathology · 2021Review
- Burden of Disease in Patients With Tumor-Induced Osteomalacia.JBMR plus · 2021Article
- FGF23-related hypophosphatemia in patients with low bone mineral density and fragility fractures: challenges in diagnosis and management.Journal of endocrinological investigation · 2020Article
- Tumour-induced osteomalacia due to an intra-abdominal mesenchymal tumour.BMJ case reports · 2019Article
- Tumor induced osteomalacia in head and neck region: single center experience and systematic review.Endocrine connections · 2019Article
- Phosphaturic mesenchymal tumors: what an endocrinologist should know.Journal of endocrinological investigation · 2018Review
- Yield of diagnostic tests in unexplained renal hypophosphatemia: a case series.BMC nephrology · 2018Article
- Tumor-induced osteomalacia.Bone reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The majority of tumor-induced osteomalacia cases have been reported in the Northern Hemisphere and Asia. In this first series of South American patients, we show that the clinical presentation and sensitivity of plasmatic fibroblast growth factor 23 and somatostatin analog-based imaging are similar to those described in other populations.
introductionDescribe the experience of clinical presentation, diagnostic study, and treatment of patients with tumor-induced osteomalacia (TIO) in a South American academic center in comparison to literature.
methodsAnalysis of the records of patients diagnosed with TIO. The clinical presentation, diagnostic studies, and treatment were analyzed. Fibroblast growth factor 23 (FGF23) was measured by ELISA.
resultsSix patients were diagnosed with TIO during the studied period. The patients' median age was 53 years (range 22-64). All patients presented with weakness and pain in the extremities. Four experienced fractures during their evolution. The median time to diagnosis was 4.5 years (1-20). Biochemical studies showed hypophosphatemia, median of 1.4 mg/dL (1.2-1.6), with low maximum rates of tubular reabsorption of phosphate adjusted for glomerular filtration rate. FGF23 was elevated in 4/6 patients and inappropriately normal in the other two. In three patients, the location of the tumor was clinically evident and confirmed with anatomical imaging. In the remaining patients, two tumors were located with
conclusionsThe clinical presentation, delay time to diagnosis, FGF23 diagnostic sensitivity and histopathology in this first series of South American patients is similar to those described in other populations. The success of localization by somatostatin analog-based imaging, suggests this may the optimal imaging modality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.